Skip to content

Contact
Careers

<img width="197" height="109" src="https://tffpharma.com/wp-content/uploads/2022/08/TFF-Pharmaceuticals-Logo.svg" class="custom-logo astra-logo-svg" alt="TFF Pharamceuticals Logo" decoding="async" />

About
Platform Technology
Programs
Collaborations
Resources
Investors

About
Platform Technology
Programs
Collaborations
Resources
Investors

<img width="197" height="109" src="https://tffpharma.com/wp-content/uploads/2022/08/TFF-Pharmaceuticals-Logo.svg" class="custom-logo astra-logo-svg" alt="TFF Pharamceuticals Logo" decoding="async" />

About
Platform Technology
Programs
Collaborations
Resources
Investors

Contact
Careers

Privacy Policy
Accessibility Statement

News

tff pharma investors hero

Sort by Year
Search

October 2, 2023

TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines

September 28, 2023

TFF Pharmaceuticals to Participate in Upcoming Investor Conferences

August 23, 2023

TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023

August 17, 2023

TFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

August 15, 2023

TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 15, 2023

TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock

August 14, 2023

TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock

August 9, 2023

TFF Pharmaceuticals to Hold Second Quarter 2023 Financial and Business Results Conference Call on August 15, 2023

July 31, 2023

TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded Access Program for Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infections

June 26, 2023

TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine

IR Contact Information

Corey Davis, Ph.D.
LifeSci Advisors
Tel: +212-915-2577
cdavis@lifesciadvisors.com

Bill Begien

TFF Pharmaceuticals, Inc.

bbegien@tffpharma.com

Email Alerts Sign-Up

Email

SEC Filings

Press Releases

End of Day Stock Quote

Company

About
Management Team
Board of Directors
Scientific Advisory Board
Careers
Contact

Technology

Platform Technology
Thin Film Freezing Process
Platform Benefits
Pipeline
Internal Pipeline

Partnering

Collaborations
Focus Areas
Pharma
Academic
Government
CDMO
FCOI Policy

Investors

Overview
News
Events
SEC Filings
Corporate Governance
Stock Information
FAQs

Copyright © 2023 TFF Pharmaceuticals

Privacy Policy
Accessibility Statement